AviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal Dementias
LONDON -- AviadoBio , a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, will present preliminary data at the 15th International Conference on Frontotemporal Dementias showing early signs of dose-dependent increases in cerebrospinal fluid (CSF) progranulin across four ascending doses in its ongoing Phase 1/2 ASPIRE-FTD clinical trial evaluating AVB-101, its investigational gene therapy being developed for people living with frontotemporal dementia with GRN mutations (FTD-GRN).
Read More
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.